Drug or technology

Calderasib

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 8, 2026 · PHASE 3 TRIAL

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

ClinicalTrials.gov

This is a Phase 3 trial registration with no results posted; the study is actively recruiting and has not yet reported efficacy or safety outcomes.

PreliminaryNCT06345729 Merck Sharp & Dohme Pembrolizumab

Reported

Estimated enrollment600

PhasePhase 3

Primary endpoint 1Progression-Free Survival (PFS), up to appr…

AUG 17, 2026 · PHASE 3 TRIAL

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

ClinicalTrials.gov

Phase 3 randomized controlled trial currently recruiting with no results reported; registry record describes planned design and endpoints only.

PreliminaryNCT07431827 Merck Sharp & Dohme MK-3475A

Reported

Planned enrollment400

PhasePhase 3

Primary endpointDisease-free Survival (DFS), up to ~11 years

AUG 7, 2026 · PHASE 3 TRIAL

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

ClinicalTrials.gov

This is a Phase 3 trial registration with no results posted; enrollment is ongoing and outcomes have not yet been reported.

PreliminaryNCT07554339 Placebo to MK-1084 Merck Sharp & Dohme

Reported

Planned enrollment310

PhasePHASE 3

Primary endpointProgression-Free Survival (PFS), up to appr…